Modulation of Central Hypersensitivity in Chronic Musculoskeletal Pain by Intravenous Tropisetron
CompletedPhase 2NCT00889499
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Chronic pain is associated with hypersensitivity of the central nervous system. The drug under investigation (tropisetron) has been shown in animal studies to attenuate central hypersensitivity. It has therefore the potential to be effective in chronic pain. We compare two doses of tropisetron with placebo in patients with chronic pain. We measure pain intensity and parameters that assess central hypersensitivity.
Study details
- Official title
- Modulation of Central Hypersensitivity in Chronic Musculoskeletal Pain by Intravenous Tropisetron
- Conditions
- Interventions
- Drug: Tropisetron 2 mg
- Drug: Tropisetron 5mg
- Drug: Placebo
- Sponsor
- Insel Gruppe AG, University Hospital Bern
- Start date
- 2009-03
- Primary completion
- 2010-04
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Switzerland
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Chronic musculoskeletal pain * Pain duration at least 6 months Exclusion Criteria: * Pregnancy * Breast feeding
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00889499